Gamma Delta T Cell Cancer Therapy Market By Clinical Indication (Solid Tumor, Hematological Cancer, Non-Hodgkin’s lymphoma, Multiple Myeloma, Chronic lymphocytic leukemia and Melanoma, Pancreatic Cancer, Prostate Cancer, Colorectal Cancer, Others); By Therapies (ADI-001, LAVA-051, INB-200, TCB002, INB-100, GDX012, AVM0703, Others); By Clinical Trials (Research, Preclinical, Phase-I, Phase-II/III); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
In the last few years, researchers were able to identify gamma delta T cells, which have a crucial significance in cancer immunotherapy to overcome the limitations of adoptive cell treatment. Advances in biotechnology and the present understanding of T cell engineering have led to new techniques in this struggle, resulting in a better cell-mediated immune response to cancer. For instance, TC Biopharm is seeking to use this innate function to create a new type of gamma delta T cell treatment, wherein it is feasible to develop a supercharged cell with dramatically improved cytotoxicity against cancerous tissues. Moreover, prominent companies in the global gamma delta T cell cancer therapy market are undertaking strategic initiatives to expand their immuno-oncology offerings. For instance, in October 2021, Takeda Pharmaceutical Company Limited announced the acquisition of GammaDelta Therapeutics Limited to strengthen their unique properties of gamma delta (γδ) T cells for immunotherapy. This acquisition will help Takeda to find and accelerate the development of the most promising ideas that can be turned into products, which will have a positive influence on the lives of cancer patients'. Moreover government organizations and private institutions are massively investing into further research and development for gamma delta T cell cancer therapy for effective results, which is anticipated to drive the growth of global gamma delta T cell cancer therapy market over the forecast period.
Gamma Delta T Cell Cancer Therapy Market Revenue & Forecast, (US$ Million), 2015 – 2030
Clinical Indication Outlook:
Based clinical indication, the global gamma delta T cell cancer therapy market is segmented into solid tumor, hematological cancer, non-hodgkin’s lymphoma, multiple myeloma, chronic lymphocytic leukemia and melanoma, pancreatic cancer, prostate cancer, colorectal cancer and others. Cellular treatments have altered cancer immunotherapy in the last decade. Following the FDA approval of antigen receptor (CAR) T cell treatments, adoptive T cell therapies have been extensively studied in preclinical and clinical stages. Furthermore, the most common type of leukaemia is chronic lymphocytic leukaemia, or CLL. Novel targeted treatments have altered the treatment algorithm for chronic lymphocytic leukaemia. Gamma delta T cell therapy for the treatment of lymphoid malignancies has improved the disease response and survival outcomes of several forms of relapsed and/or refractory B cell lymphomas because of advances in immuno-oncology and T cell engineering.
Therapies Outlook:
Based on therapies, the gamma delta T cell cancer therapy market is segmented into ADI-001, LAVA-051, INB-200, TCB002, INB-100, GDX012, AVM0703 and others. Leading players in the market are focusing on the further development and innovation of therapies for the cancer treatments. Moreover, government organizations across regions are encouraging the research and development of these therapies on a large scale. For instance, In October 2020, ADI-001, an allogeneic chimeric antigen receptor gamma-delta T-cell therapy, for the treatment of relapsed or refractory non-Hodgkin lymphoma, received FDA approval as an experimental novel medication. This significant step forward by the company, Adicet Bio has led to a huge development of CAR gamma-delta T-cell therapies, since it signals the start of clinical development of a broad pipeline of gamma-delta T-cell products. Thus, such advancements in therapies is boosting the gamma delta T cell cancer therapy market globally.
Clinical Trails Outlook:
On the basis of clinical trials, the global gamma delta T cell cancer therapy market is classified into research, preclinical, Phase-I and Phase-II/III. Pre-clinical research, phase 1 and phase 2 clinical trials are gaining popularity in the market, as leading players are investing into advanced technologies and innovations for better results of the cancer therapies. For instance, IN8bio, a clinical-stage biopharmaceutical company, that has developed a number of innovative gamma-delta T-cell therapies utilising its proprietary DeltEx platform, shared updates from the ongoing Phase 1 clinical trial of INB-200, which is being developed to treat cancer, in an attempt to meet an unmet medical need. For its lead gamma-delta T cell product prospects, the company is currently undertaking two investigator-initiated Phase 1 clinical trials. INB-200 is used to treat newly diagnosed glioblastoma, while INB-100 is used to treat leukaemia patients undergoing hematopoietic stem cell transplantation. Thus with such initiatives by the leading players, the gamma delta T cell cancer therapy market is experiencing tremendous growth globally.
Region Outlook:
North America held the highest share in the global gamma delta T cell cancer therapy market in 2021, due to high adoption rates of novel cancer immunotherapy and high prevalence of cancer in this region. In the United States, 1,806,590 new cases of cancer were identified in 2021, with 606,520 people dying from the disease. The most common types of cancer found in the Unites States are prostate cancer, Non-Hodgkin's lymphoma, haematological cancer which has led to a high rate in adoption of gamma delta T cell. Leading players in the market are investing into mergers and collaboration to expand and strengthen their product offerings for gamma delta T cell cancer therapy. Furthermore, healthcare organizations and government institutions are investing into healthcare research and development activities to strengthen their healthcare infrastructure, which will contribute towards the growth of gamma delta T cell cancer therapy market.
Competitive Landscape
The report provides both, qualitative and quantitative research of global gamma delta T cell cancer therapy market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global gamma delta T cell cancer therapy market are:
- Acepodia
- Adicet Bio
- AVM Biotechnology
- Gadeta Therapeutics
- GammaDelta Therapeutics
- IN8bio
- Kiromic Biopharma
- Lava Therapeutics
- Takeda Pharmaceuticals
- TC Biopharm
- Other Industry Participants.
Global Gamma Delta T Cell Cancer Therapy Market:
- By Clinical Indication
- Solid Tumor
- Hematological Cancer
- Non-Hodgkin’s lymphoma
- Multiple Myeloma
- Chronic lymphocytic leukemia and Melanoma
- Pancreatic Cancer
- Prostate Cancer
- Colorectal Cancer
- Others
- By Therapies
- ADI-001
- LAVA-051
- INB-200
- TCB002
- INB-100
- GDX012
- AVM0703
- Others
- By Clinical Trials
- Research
- Preclinical
- Phase-I
- Phase-II/III
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2021
1.2.2. Base
Year: 2021
1.2.3. Forecast
Years: 2022 – 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Gamma Delta T Cell Cancer Therapy Market
6. Market Synopsis: Gamma
Delta T Cell Cancer Therapy Market
7. Gamma Delta T Cell Cancer Therapy Market Analysis:
Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Gamma Delta T Cell Cancer Therapy Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Gamma Delta T Cell Cancer Therapy Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Gamma Delta T Cell Cancer Therapy Market
8. Global Gamma Delta T Cell Cancer Therapy Market Analysis and
Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global
Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn)
8.2. Global
Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Indication
8.2.1. Solid
Tumor
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2021
8.2.1.3. Market Forecast, 2022 - 2030
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2021
8.2.1.5.1.2. Market
Forecast, 2022 - 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2021
8.2.1.5.2.2. Market
Forecast, 2022 - 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2021
8.2.1.5.3.2. Market
Forecast, 2022 - 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2021
8.2.1.5.4.2. Market
Forecast, 2022 - 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2021
8.2.1.5.5.2. Market
Forecast, 2022 - 2030
8.2.2. Haematological
Cancer
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2021
8.2.2.3. Market Forecast, 2022 - 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2021
8.2.2.5.1.2. Market
Forecast, 2022 - 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2021
8.2.2.5.2.2. Market
Forecast, 2022 - 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2021
8.2.2.5.3.2. Market
Forecast, 2022 - 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2021
8.2.2.5.4.2. Market
Forecast, 2022 - 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2021
8.2.2.5.5.2. Market
Forecast, 2022 - 2030
8.2.3. Non-Hodgkin’s
lymphoma
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2021
8.2.3.3. Market Forecast, 2022 - 2030
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2021
8.2.3.5.1.2. Market
Forecast, 2022 - 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2021
8.2.3.5.2.2. Market
Forecast, 2022 - 2030
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2021
8.2.3.5.3.2. Market
Forecast, 2022 - 2030
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2021
8.2.3.5.4.2. Market
Forecast, 2022 - 2030
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2021
8.2.3.5.5.2. Market
Forecast, 2022 - 2030
8.2.4. Multiple
Myeloma
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2021
8.2.4.3. Market Forecast, 2022 - 2030
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market
Estimation, 2015 - 2021
8.2.4.5.1.2. Market
Forecast, 2022 - 2030
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 - 2021
8.2.4.5.2.2. Market
Forecast, 2022 - 2030
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market
Estimation, 2015 - 2021
8.2.4.5.3.2. Market
Forecast, 2022 - 2030
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 - 2021
8.2.4.5.4.2. Market
Forecast, 2022 - 2030
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market
Estimation, 2015 - 2021
8.2.4.5.5.2. Market
Forecast, 2022 - 2030
8.2.5. Chronic
lymphocytic leukemia and Melanoma
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 - 2021
8.2.5.3. Market Forecast, 2022 - 2030
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market
Estimation, 2015 - 2021
8.2.5.5.1.2. Market
Forecast, 2022 - 2030
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2015 - 2021
8.2.5.5.2.2. Market
Forecast, 2022 - 2030
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market
Estimation, 2015 - 2021
8.2.5.5.3.2. Market
Forecast, 2022 - 2030
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market
Estimation, 2015 - 2021
8.2.5.5.4.2. Market
Forecast, 2022 - 2030
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market
Estimation, 2015 - 2021
8.2.5.5.5.2. Market
Forecast, 2022 - 2030
8.2.6. Pancreatic
Cancer
8.2.6.1. Definition
8.2.6.2. Market Estimation and Penetration, 2015 - 2021
8.2.6.3. Market Forecast, 2022 - 2030
8.2.6.4. Compound Annual Growth Rate (CAGR)
8.2.6.5. Regional Bifurcation
8.2.6.5.1. North America
8.2.6.5.1.1. Market
Estimation, 2015 - 2021
8.2.6.5.1.2. Market
Forecast, 2022 - 2030
8.2.6.5.2. Europe
8.2.6.5.2.1. Market
Estimation, 2015 - 2021
8.2.6.5.2.2. Market
Forecast, 2022 - 2030
8.2.6.5.3. Asia Pacific
8.2.6.5.3.1. Market
Estimation, 2015 - 2021
8.2.6.5.3.2. Market
Forecast, 2022 - 2030
8.2.6.5.4. Middle East and Africa
8.2.6.5.4.1. Market
Estimation, 2015 - 2021
8.2.6.5.4.2. Market
Forecast, 2022 - 2030
8.2.6.5.5. Latin America
8.2.6.5.5.1. Market
Estimation, 2015 - 2021
8.2.6.5.5.2. Market
Forecast, 2022 - 2030
8.2.7. Prostate
Cancer
8.2.7.1. Definition
8.2.7.2. Market Estimation and Penetration, 2015 - 2021
8.2.7.3. Market Forecast, 2022 - 2030
8.2.7.4. Compound Annual Growth Rate (CAGR)
8.2.7.5. Regional Bifurcation
8.2.7.5.1. North America
8.2.7.5.1.1. Market
Estimation, 2015 - 2021
8.2.7.5.1.2. Market
Forecast, 2022 - 2030
8.2.7.5.2. Europe
8.2.7.5.2.1. Market
Estimation, 2015 - 2021
8.2.7.5.2.2. Market
Forecast, 2022 - 2030
8.2.7.5.3. Asia Pacific
8.2.7.5.3.1. Market
Estimation, 2015 - 2021
8.2.7.5.3.2. Market
Forecast, 2022 - 2030
8.2.7.5.4. Middle East and Africa
8.2.7.5.4.1. Market
Estimation, 2015 - 2021
8.2.7.5.4.2. Market
Forecast, 2022 - 2030
8.2.7.5.5. Latin America
8.2.7.5.5.1. Market
Estimation, 2015 - 2021
8.2.7.5.5.2. Market
Forecast, 2022 - 2030
8.2.8. Colorectal
Cancer
8.2.8.1. Definition
8.2.8.2. Market Estimation and Penetration, 2015 - 2021
8.2.8.3. Market Forecast, 2022 - 2030
8.2.8.4. Compound Annual Growth Rate (CAGR)
8.2.8.5. Regional Bifurcation
8.2.8.5.1. North America
8.2.8.5.1.1. Market
Estimation, 2015 - 2021
8.2.8.5.1.2. Market
Forecast, 2022 - 2030
8.2.8.5.2. Europe
8.2.8.5.2.1. Market
Estimation, 2015 - 2021
8.2.8.5.2.2. Market
Forecast, 2022 - 2030
8.2.8.5.3. Asia Pacific
8.2.8.5.3.1. Market
Estimation, 2015 - 2021
8.2.8.5.3.2. Market
Forecast, 2022 - 2030
8.2.8.5.4. Middle East and Africa
8.2.8.5.4.1. Market
Estimation, 2015 - 2021
8.2.8.5.4.2. Market
Forecast, 2022 - 2030
8.2.8.5.5. Latin America
8.2.8.5.5.1. Market
Estimation, 2015 - 2021
8.2.8.5.5.2. Market
Forecast, 2022 - 2030
8.2.9. Others
8.2.9.1. Definition
8.2.9.2. Market Estimation and Penetration, 2015 - 2021
8.2.9.3. Market Forecast, 2022 - 2030
8.2.9.4. Compound Annual Growth Rate (CAGR)
8.2.9.5. Regional Bifurcation
8.2.9.5.1. North America
8.2.9.5.1.1. Market
Estimation, 2015 - 2021
8.2.9.5.1.2. Market
Forecast, 2022 - 2030
8.2.9.5.2. Europe
8.2.9.5.2.1. Market
Estimation, 2015 - 2021
8.2.9.5.2.2. Market
Forecast, 2022 - 2030
8.2.9.5.3. Asia Pacific
8.2.9.5.3.1. Market
Estimation, 2015 - 2021
8.2.9.5.3.2. Market
Forecast, 2022 - 2030
8.2.9.5.4. Middle East and Africa
8.2.9.5.4.1. Market
Estimation, 2015 - 2021
8.2.9.5.4.2. Market
Forecast, 2022 - 2030
8.2.9.5.5. Latin America
8.2.9.5.5.1. Market
Estimation, 2015 - 2021
8.2.9.5.5.2. Market
Forecast, 2022 - 2030
8.3. Key
Segment for Channeling Investments
8.3.1. By
Clinical Indication
9. Global Gamma Delta T Cell Cancer Therapy Market Analysis and
Forecasts, 2022 – 2030
9.1. Overview
9.2. Global
Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapies
9.2.1. ADI-001
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2021
9.2.1.3. Market Forecast, 2022 - 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2021
9.2.1.5.1.2. Market
Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2021
9.2.1.5.2.2. Market
Forecast, 2022 - 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2021
9.2.1.5.3.2. Market
Forecast, 2022 - 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2021
9.2.1.5.4.2. Market
Forecast, 2022 - 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2021
9.2.1.5.5.2. Market
Forecast, 2022 - 2030
9.2.2. LAVA-051
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2021
9.2.2.3. Market Forecast, 2022 - 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2021
9.2.2.5.1.2. Market
Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2021
9.2.2.5.2.2. Market
Forecast, 2022 - 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2021
9.2.2.5.3.2. Market
Forecast, 2022 - 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2021
9.2.2.5.4.2. Market
Forecast, 2022 - 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2021
9.2.2.5.5.2. Market
Forecast, 2022 - 2030
9.2.3. INB-200
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2021
9.2.3.3. Market Forecast, 2022 - 2030
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2021
9.2.3.5.1.2. Market
Forecast, 2022 - 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2021
9.2.3.5.2.2. Market
Forecast, 2022 - 2030
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2021
9.2.3.5.3.2. Market
Forecast, 2022 - 2030
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2021
9.2.3.5.4.2. Market
Forecast, 2022 - 2030
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2021
9.2.3.5.5.2. Market
Forecast, 2022 - 2030
9.2.4. TCB002
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2021
9.2.4.3. Market Forecast, 2022 - 2030
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2021
9.2.4.5.1.2. Market
Forecast, 2022 - 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2021
9.2.4.5.2.2. Market
Forecast, 2022 - 2030
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2021
9.2.4.5.3.2. Market
Forecast, 2022 - 2030
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2021
9.2.4.5.4.2. Market
Forecast, 2022 - 2030
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2021
9.2.4.5.5.2. Market
Forecast, 2022 - 2030
9.2.5. INB-100
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2021
9.2.5.3. Market Forecast, 2022 - 2030
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2021
9.2.5.5.1.2. Market
Forecast, 2022 - 2030
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2021
9.2.5.5.2.2. Market
Forecast, 2022 - 2030
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2021
9.2.5.5.3.2. Market
Forecast, 2022 - 2030
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2021
9.2.5.5.4.2. Market
Forecast, 2022 - 2030
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2021
9.2.5.5.5.2. Market
Forecast, 2022 - 2030
9.2.6. GDX012
9.2.6.1. Definition
9.2.6.2. Market Estimation and Penetration, 2015 - 2021
9.2.6.3. Market Forecast, 2022 - 2030
9.2.6.4. Compound Annual Growth Rate (CAGR)
9.2.6.5. Regional Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1. Market
Estimation, 2015 - 2021
9.2.6.5.1.2. Market
Forecast, 2022 - 2030
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 - 2021
9.2.6.5.2.2. Market
Forecast, 2022 - 2030
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1. Market
Estimation, 2015 - 2021
9.2.6.5.3.2. Market
Forecast, 2022 - 2030
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 - 2021
9.2.6.5.4.2. Market
Forecast, 2022 - 2030
9.2.6.5.5. Latin America
9.2.6.5.5.1. Market
Estimation, 2015 - 2021
9.2.6.5.5.2. Market
Forecast, 2022 - 2030
9.2.7. AVM0703
9.2.7.1. Definition
9.2.7.2. Market Estimation and Penetration, 2015 - 2021
9.2.7.3. Market Forecast, 2022 - 2030
9.2.7.4. Compound Annual Growth Rate (CAGR)
9.2.7.5. Regional Bifurcation
9.2.7.5.1. North America
9.2.7.5.1.1. Market
Estimation, 2015 - 2021
9.2.7.5.1.2. Market
Forecast, 2022 - 2030
9.2.7.5.2. Europe
9.2.7.5.2.1. Market
Estimation, 2015 - 2021
9.2.7.5.2.2. Market
Forecast, 2022 - 2030
9.2.7.5.3. Asia Pacific
9.2.7.5.3.1. Market
Estimation, 2015 - 2021
9.2.7.5.3.2. Market
Forecast, 2022 - 2030
9.2.7.5.4. Middle East and Africa
9.2.7.5.4.1. Market
Estimation, 2015 - 2021
9.2.7.5.4.2. Market
Forecast, 2022 - 2030
9.2.7.5.5. Latin America
9.2.7.5.5.1. Market
Estimation, 2015 - 2021
9.2.7.5.5.2. Market
Forecast, 2022 - 2030
9.2.8. Others
9.2.8.1. Definition
9.2.8.2. Market Estimation and Penetration, 2015 - 2021
9.2.8.3. Market Forecast, 2022 - 2030
9.2.8.4. Compound Annual Growth Rate (CAGR)
9.2.8.5. Regional Bifurcation
9.2.8.5.1. North America
9.2.8.5.1.1. Market
Estimation, 2015 - 2021
9.2.8.5.1.2. Market
Forecast, 2022 - 2030
9.2.8.5.2. Europe
9.2.8.5.2.1. Market
Estimation, 2015 - 2021
9.2.8.5.2.2. Market
Forecast, 2022 - 2030
9.2.8.5.3. Asia Pacific
9.2.8.5.3.1. Market
Estimation, 2015 - 2021
9.2.8.5.3.2. Market
Forecast, 2022 - 2030
9.2.8.5.4. Middle East and Africa
9.2.8.5.4.1. Market
Estimation, 2015 - 2021
9.2.8.5.4.2. Market
Forecast, 2022 - 2030
9.2.8.5.5. Latin America
9.2.8.5.5.1. Market
Estimation, 2015 - 2021
9.2.8.5.5.2. Market
Forecast, 2022 - 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By
Therapies
10. Global Gamma Delta T Cell Cancer Therapy Market Analysis and
Forecasts, 2022 – 2030
10.1. Overview
10.2. Global
Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
10.2.1. Research
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2021
10.2.1.3. Market Forecast, 2022 - 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2021
10.2.1.5.1.2. Market
Forecast, 2022 - 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2021
10.2.1.5.2.2. Market
Forecast, 2022 - 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2021
10.2.1.5.3.2. Market
Forecast, 2022 - 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2021
10.2.1.5.4.2. Market
Forecast, 2022 - 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2021
10.2.1.5.5.2. Market
Forecast, 2022 - 2030
10.2.2. Preclinical
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2021
10.2.2.3. Market Forecast, 2022 - 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2021
10.2.2.5.1.2. Market
Forecast, 2022 - 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2021
10.2.2.5.2.2. Market
Forecast, 2022 - 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2021
10.2.2.5.3.2. Market
Forecast, 2022 - 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2021
10.2.2.5.4.2. Market
Forecast, 2022 - 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2021
10.2.2.5.5.2. Market
Forecast, 2022 - 2030
10.2.3. Phase-I
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2021
10.2.3.3. Market Forecast, 2022 - 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2021
10.2.3.5.1.2. Market
Forecast, 2022 - 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2021
10.2.3.5.2.2. Market
Forecast, 2022 - 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2021
10.2.3.5.3.2. Market
Forecast, 2022 - 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2021
10.2.3.5.4.2. Market
Forecast, 2022 - 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2021
10.2.3.5.5.2. Market
Forecast, 2022 - 2030
10.2.4. Phase-II/III
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2021
10.2.4.3. Market Forecast, 2022 - 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2021
10.2.4.5.1.2. Market
Forecast, 2022 - 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2021
10.2.4.5.2.2. Market
Forecast, 2022 - 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2021
10.2.4.5.3.2. Market
Forecast, 2022 - 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2021
10.2.4.5.4.2. Market
Forecast, 2022 - 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2021
10.2.4.5.5.2. Market
Forecast, 2022 - 2030
10.3. Key Segment
for Channeling Investments
10.3.1. By
Clinical Trials
11. North America Gamma Delta T Cell Cancer Therapy Market
Analysis and Forecasts, 2022 - 2030
11.1. Overview
11.1.1. North
America Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn)
11.2. North
America Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Clinical Indication
11.2.1. Solid
Tumor
11.2.2. Haematological
Cancer
11.2.3. Non-Hodgkin’s
lymphoma
11.2.4. Multiple
Myeloma
11.2.5. Chronic
lymphocytic leukemia and Melanoma
11.2.6. Pancreatic
Cancer
11.2.7. Prostate
Cancer
11.2.8. Colorectal
Cancer
11.2.9. Others
11.3. North
America Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapies
11.3.1. ADI-001
11.3.2. LAVA-051
11.3.3. INB-200
11.3.4. TCB002
11.3.5. INB-100
11.3.6. GDX012
11.3.7. AVM0703
11.3.8. Others
11.4. North
America Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Clinical Trials
11.4.1. Research
11.4.2. Preclinical
11.4.3. Phase-I
11.4.4. Phase-II/III
11.5. North
America Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Indication
11.5.1.1.1. Solid Tumor
11.5.1.1.2. Haematological Cancer
11.5.1.1.3. Non-Hodgkin’s lymphoma
11.5.1.1.4. Multiple Myeloma
11.5.1.1.5. Chronic lymphocytic leukemia and Melanoma
11.5.1.1.6. Pancreatic Cancer
11.5.1.1.7. Prostate Cancer
11.5.1.1.8. Colorectal Cancer
11.5.1.1.9. Others
11.5.1.2. U.S Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn)
and Forecasts, By Therapies
11.5.1.2.1. ADI-001
11.5.1.2.2. LAVA-051
11.5.1.2.3. INB-200
11.5.1.2.4. TCB002
11.5.1.2.5. INB-100
11.5.1.2.6. GDX012
11.5.1.2.7. AVM0703
11.5.1.2.8. Others
11.5.1.3. U.S Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trials
11.5.1.3.1. Research
11.5.1.3.2. Preclinical
11.5.1.3.3. Phase-I
11.5.1.3.4. Phase-II/III
11.5.2. Canada
11.5.2.1. Canada Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Indication
11.5.2.1.1. Solid Tumor
11.5.2.1.2. Haematological Cancer
11.5.2.1.3. Non-Hodgkin’s lymphoma
11.5.2.1.4. Multiple Myeloma
11.5.2.1.5. Chronic lymphocytic leukemia and Melanoma
11.5.2.1.6. Pancreatic Cancer
11.5.2.1.7. Prostate Cancer
11.5.2.1.8. Colorectal Cancer
11.5.2.1.9. Others
11.5.2.2. Canada Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Therapies
11.5.2.2.1. ADI-001
11.5.2.2.2. LAVA-051
11.5.2.2.3. INB-200
11.5.2.2.4. TCB002
11.5.2.2.5. INB-100
11.5.2.2.6. GDX012
11.5.2.2.7. AVM0703
11.5.2.2.8. Others
11.5.2.3. Canada Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trials
11.5.2.3.1. Research
11.5.2.3.2. Preclinical
11.5.2.3.3. Phase-I
11.5.2.3.4. Phase-II/III
11.5.3. Mexico
11.5.3.1. Mexico Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Indication
11.5.3.1.1. Solid Tumor
11.5.3.1.2. Haematological Cancer
11.5.3.1.3. Non-Hodgkin’s lymphoma
11.5.3.1.4. Multiple Myeloma
11.5.3.1.5. Chronic lymphocytic leukemia and Melanoma
11.5.3.1.6. Pancreatic Cancer
11.5.3.1.7. Prostate Cancer
11.5.3.1.8. Colorectal Cancer
11.5.3.1.9. Others
11.5.3.2. Mexico Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Therapies
11.5.3.2.1. ADI-001
11.5.3.2.2. LAVA-051
11.5.3.2.3. INB-200
11.5.3.2.4. TCB002
11.5.3.2.5. INB-100
11.5.3.2.6. GDX012
11.5.3.2.7. AVM0703
11.5.3.2.8. Others
11.5.3.3. Mexico Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trials
11.5.3.3.1. Research
11.5.3.3.2. Preclinical
11.5.3.3.3. Phase-I
11.5.3.3.4. Phase-II/III
11.5.4. Rest of
North America
11.5.4.1. Rest of North America Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Indication
11.5.4.1.1. Solid Tumor
11.5.4.1.2. Haematological Cancer
11.5.4.1.3. Non-Hodgkin’s lymphoma
11.5.4.1.4. Multiple Myeloma
11.5.4.1.5. Chronic lymphocytic leukemia and Melanoma
11.5.4.1.6. Pancreatic Cancer
11.5.4.1.7. Prostate Cancer
11.5.4.1.8. Colorectal Cancer
11.5.4.1.9. Others
11.5.4.2. Rest of North America Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Therapies
11.5.4.2.1. ADI-001
11.5.4.2.2. LAVA-051
11.5.4.2.3. INB-200
11.5.4.2.4. TCB002
11.5.4.2.5. INB-100
11.5.4.2.6. GDX012
11.5.4.2.7. AVM0703
11.5.4.2.8. Others
11.5.4.3. Rest of North America Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trials
11.5.4.3.1. Research
11.5.4.3.2. Preclinical
11.5.4.3.3. Phase-I
11.5.4.3.4. Phase-II/III
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By
Clinical Indication
11.6.3. By
Therapies
11.6.4. By
Clinical Trials
12. Europe Gamma Delta T Cell Cancer Therapy Market Analysis and
Forecasts, 2022 - 2030
12.1. Overview
12.1.1. Europe
Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn)
12.2. Europe
Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Indication
12.2.1. Solid
Tumor
12.2.2. Haematological
Cancer
12.2.3. Non-Hodgkin’s
lymphoma
12.2.4. Multiple
Myeloma
12.2.5. Chronic
lymphocytic leukemia and Melanoma
12.2.6. Pancreatic
Cancer
12.2.7. Prostate
Cancer
12.2.8. Colorectal
Cancer
12.2.9. Others
12.3. Europe
Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapies
12.3.1. ADI-001
12.3.2. LAVA-051
12.3.3. INB-200
12.3.4. TCB002
12.3.5. INB-100
12.3.6. GDX012
12.3.7. AVM0703
12.3.8. Others
12.4. Europe
Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and Forecasts, By
Clinical Trials
12.4.1. Research
12.4.2. Preclinical
12.4.3. Phase-I
12.4.4. Phase-II/III
12.5. Europe
Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and Forecasts, By
Country
12.5.1. France
12.5.1.1. France Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Indication
12.5.1.1.1. Solid Tumor
12.5.1.1.2. Haematological Cancer
12.5.1.1.3. Non-Hodgkin’s lymphoma
12.5.1.1.4. Multiple Myeloma
12.5.1.1.5. Chronic lymphocytic leukemia and Melanoma
12.5.1.1.6. Pancreatic Cancer
12.5.1.1.7. Prostate Cancer
12.5.1.1.8. Colorectal Cancer
12.5.1.1.9. Others
12.5.1.2. France Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Therapies
12.5.1.2.1. ADI-001
12.5.1.2.2. LAVA-051
12.5.1.2.3. INB-200
12.5.1.2.4. TCB002
12.5.1.2.5. INB-100
12.5.1.2.6. GDX012
12.5.1.2.7. AVM0703
12.5.1.2.8. Others
12.5.1.3. France Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trials
12.5.1.3.1. Research
12.5.1.3.2. Preclinical
12.5.1.3.3. Phase-I
12.5.1.3.4. Phase-II/III
12.5.2. The UK
12.5.2.1. The UK Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Indication
12.5.2.1.1. Solid Tumor
12.5.2.1.2. Haematological Cancer
12.5.2.1.3. Non-Hodgkin’s lymphoma
12.5.2.1.4. Multiple Myeloma
12.5.2.1.5. Chronic lymphocytic leukemia and Melanoma
12.5.2.1.6. Pancreatic Cancer
12.5.2.1.7. Prostate Cancer
12.5.2.1.8. Colorectal Cancer
12.5.2.1.9. Others
12.5.2.2. The UK Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Therapies
12.5.2.2.1. ADI-001
12.5.2.2.2. LAVA-051
12.5.2.2.3. INB-200
12.5.2.2.4. TCB002
12.5.2.2.5. INB-100
12.5.2.2.6. GDX012
12.5.2.2.7. AVM0703
12.5.2.2.8. Others
12.5.2.3. The UK Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trials
12.5.2.3.1. Research
12.5.2.3.2. Preclinical
12.5.2.3.3. Phase-I
12.5.2.3.4. Phase-II/III
12.5.3. Spain
12.5.3.1. Spain Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Indication
12.5.3.1.1. Solid Tumor
12.5.3.1.2. Haematological Cancer
12.5.3.1.3. Non-Hodgkin’s lymphoma
12.5.3.1.4. Multiple Myeloma
12.5.3.1.5. Chronic lymphocytic leukemia and Melanoma
12.5.3.1.6. Pancreatic Cancer
12.5.3.1.7. Prostate Cancer
12.5.3.1.8. Colorectal Cancer
12.5.3.1.9. Others
12.5.3.2. Spain Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Therapies
12.5.3.2.1. ADI-001
12.5.3.2.2. LAVA-051
12.5.3.2.3. INB-200
12.5.3.2.4. TCB002
12.5.3.2.5. INB-100
12.5.3.2.6. GDX012
12.5.3.2.7. AVM0703
12.5.3.2.8. Others
12.5.3.3. Spain Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trials
12.5.3.3.1. Research
12.5.3.3.2. Preclinical
12.5.3.3.3. Phase-I
12.5.3.3.4. Phase-II/III
12.5.4. Germany
12.5.4.1. Germany Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Indication
12.5.4.1.1. Solid Tumor
12.5.4.1.2. Haematological Cancer
12.5.4.1.3. Non-Hodgkin’s lymphoma
12.5.4.1.4. Multiple Myeloma
12.5.4.1.5. Chronic lymphocytic leukemia and Melanoma
12.5.4.1.6. Pancreatic Cancer
12.5.4.1.7. Prostate Cancer
12.5.4.1.8. Colorectal Cancer
12.5.4.1.9. Others
12.5.4.2. Germany Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Therapies
12.5.4.2.1. ADI-001
12.5.4.2.2. LAVA-051
12.5.4.2.3. INB-200
12.5.4.2.4. TCB002
12.5.4.2.5. INB-100
12.5.4.2.6. GDX012
12.5.4.2.7. AVM0703
12.5.4.2.8. Others
12.5.4.3. Germany Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trials
12.5.4.3.1. Research
12.5.4.3.2. Preclinical
12.5.4.3.3. Phase-I
12.5.4.3.4. Phase-II/III
12.5.5. Italy
12.5.5.1. Italy Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Indication
12.5.5.1.1. Solid Tumor
12.5.5.1.2. Haematological Cancer
12.5.5.1.3. Non-Hodgkin’s lymphoma
12.5.5.1.4. Multiple Myeloma
12.5.5.1.5. Chronic lymphocytic leukemia and Melanoma
12.5.5.1.6. Pancreatic Cancer
12.5.5.1.7. Prostate Cancer
12.5.5.1.8. Colorectal Cancer
12.5.5.1.9. Others
12.5.5.2. Italy Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Therapies
12.5.5.2.1. ADI-001
12.5.5.2.2. LAVA-051
12.5.5.2.3. INB-200
12.5.5.2.4. TCB002
12.5.5.2.5. INB-100
12.5.5.2.6. GDX012
12.5.5.2.7. AVM0703
12.5.5.2.8. Others
12.5.5.3. Italy Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trials
12.5.5.3.1. Research
12.5.5.3.2. Preclinical
12.5.5.3.3. Phase-I
12.5.5.3.4. Phase-II/III
12.5.6. Nordic
Countries
12.5.6.1. Nordic Countries Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Indication
12.5.6.1.1. Solid Tumor
12.5.6.1.2. Haematological Cancer
12.5.6.1.3. Non-Hodgkin’s lymphoma
12.5.6.1.4. Multiple Myeloma
12.5.6.1.5. Chronic lymphocytic leukemia and Melanoma
12.5.6.1.6. Pancreatic Cancer
12.5.6.1.7. Prostate Cancer
12.5.6.1.8. Colorectal Cancer
12.5.6.1.9. Others
12.5.6.2. Nordic Countries Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Therapies
12.5.6.2.1. ADI-001
12.5.6.2.2. LAVA-051
12.5.6.2.3. INB-200
12.5.6.2.4. TCB002
12.5.6.2.5. INB-100
12.5.6.2.6. GDX012
12.5.6.2.7. AVM0703
12.5.6.2.8. Others
12.5.6.3. Nordic Countries Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trials
12.5.6.3.1. Research
12.5.6.3.2. Preclinical
12.5.6.3.3. Phase-I
12.5.6.3.4. Phase-II/III
12.5.6.4. Nordic Countries Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux Union Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Indication
12.5.7.1.1. Solid Tumor
12.5.7.1.2. Haematological Cancer
12.5.7.1.3. Non-Hodgkin’s lymphoma
12.5.7.1.4. Multiple Myeloma
12.5.7.1.5. Chronic lymphocytic leukemia and Melanoma
12.5.7.1.6. Pancreatic Cancer
12.5.7.1.7. Prostate Cancer
12.5.7.1.8. Colorectal Cancer
12.5.7.1.9. Others
12.5.7.2. Benelux Union Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Therapies
12.5.7.2.1. ADI-001
12.5.7.2.2. LAVA-051
12.5.7.2.3. INB-200
12.5.7.2.4. TCB002
12.5.7.2.5. INB-100
12.5.7.2.6. GDX012
12.5.7.2.7. AVM0703
12.5.7.2.8. Others
12.5.7.3. Benelux Union Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trials
12.5.7.3.1. Research
12.5.7.3.2. Preclinical
12.5.7.3.3. Phase-I
12.5.7.3.4. Phase-II/III
12.5.7.4. Benelux Union Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest of Europe Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Indication
12.5.8.1.1. Solid Tumor
12.5.8.1.2. Haematological Cancer
12.5.8.1.3. Non-Hodgkin’s lymphoma
12.5.8.1.4. Multiple Myeloma
12.5.8.1.5. Chronic lymphocytic leukemia and Melanoma
12.5.8.1.6. Pancreatic Cancer
12.5.8.1.7. Prostate Cancer
12.5.8.1.8. Colorectal Cancer
12.5.8.1.9. Others
12.5.8.2. Rest of Europe Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Therapies
12.5.8.2.1. ADI-001
12.5.8.2.2. LAVA-051
12.5.8.2.3. INB-200
12.5.8.2.4. TCB002
12.5.8.2.5. INB-100
12.5.8.2.6. GDX012
12.5.8.2.7. AVM0703
12.5.8.2.8. Others
12.5.8.3. Rest of Europe Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trials
12.5.8.3.1. Research
12.5.8.3.2. Preclinical
12.5.8.3.3. Phase-I
12.5.8.3.4. Phase-II/III
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By
Clinical Indication
12.6.3. By
Therapies
12.6.4. By
Clinical Trials
13. Asia Pacific Gamma Delta T Cell Cancer Therapy Market
Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Asia
Pacific Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn)
13.2. Asia
Pacific Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Clinical Indication
13.2.1. Solid
Tumor
13.2.2. Haematological
Cancer
13.2.3. Non-Hodgkin’s
lymphoma
13.2.4. Multiple
Myeloma
13.2.5. Chronic
lymphocytic leukemia and Melanoma
13.2.6. Pancreatic
Cancer
13.2.7. Prostate
Cancer
13.2.8. Colorectal
Cancer
13.2.9. Others
13.3. Asia
Pacific Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapies
13.3.1. ADI-001
13.3.2. LAVA-051
13.3.3. INB-200
13.3.4. TCB002
13.3.5. INB-100
13.3.6. GDX012
13.3.7. AVM0703
13.3.8. Others
13.4. Asia
Pacific Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Clinical Trials
13.4.1. Research
13.4.2. Preclinical
13.4.3. Phase-I
13.4.4. Phase-II/III
13.5. Asia
Pacific Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Country
13.5.1. China
13.5.1.1. China Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Indication
13.5.1.1.1. Solid Tumor
13.5.1.1.2. Haematological Cancer
13.5.1.1.3. Non-Hodgkin’s lymphoma
13.5.1.1.4. Multiple Myeloma
13.5.1.1.5. Chronic lymphocytic leukemia and Melanoma
13.5.1.1.6. Pancreatic Cancer
13.5.1.1.7. Prostate Cancer
13.5.1.1.8. Colorectal Cancer
13.5.1.1.9. Others
13.5.1.2. China Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Therapies
13.5.1.2.1. ADI-001
13.5.1.2.2. LAVA-051
13.5.1.2.3. INB-200
13.5.1.2.4. TCB002
13.5.1.2.5. INB-100
13.5.1.2.6. GDX012
13.5.1.2.7. AVM0703
13.5.1.2.8. Others
13.5.1.3. China Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trials
13.5.1.3.1. Research
13.5.1.3.2. Preclinical
13.5.1.3.3. Phase-I
13.5.1.3.4. Phase-II/III
13.5.2. Japan
13.5.2.1. Japan Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Indication
13.5.2.1.1. Solid Tumor
13.5.2.1.2. Haematological Cancer
13.5.2.1.3. Non-Hodgkin’s lymphoma
13.5.2.1.4. Multiple Myeloma
13.5.2.1.5. Chronic lymphocytic leukemia and Melanoma
13.5.2.1.6. Pancreatic Cancer
13.5.2.1.7. Prostate Cancer
13.5.2.1.8. Colorectal Cancer
13.5.2.1.9. Others
13.5.2.2. Japan Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Therapies
13.5.2.2.1. ADI-001
13.5.2.2.2. LAVA-051
13.5.2.2.3. INB-200
13.5.2.2.4. TCB002
13.5.2.2.5. INB-100
13.5.2.2.6. GDX012
13.5.2.2.7. AVM0703
13.5.2.2.8. Others
13.5.2.3. Japan Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trials
13.5.2.3.1. Research
13.5.2.3.2. Preclinical
13.5.2.3.3. Phase-I
13.5.2.3.4. Phase-II/III
13.5.3. India
13.5.3.1. India Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Indication
13.5.3.1.1. Solid Tumor
13.5.3.1.2. Haematological Cancer
13.5.3.1.3. Non-Hodgkin’s lymphoma
13.5.3.1.4. Multiple Myeloma
13.5.3.1.5. Chronic lymphocytic leukemia and Melanoma
13.5.3.1.6. Pancreatic Cancer
13.5.3.1.7. Prostate Cancer
13.5.3.1.8. Colorectal Cancer
13.5.3.1.9. Others
13.5.3.2. India Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Therapies
13.5.3.2.1. ADI-001
13.5.3.2.2. LAVA-051
13.5.3.2.3. INB-200
13.5.3.2.4. TCB002
13.5.3.2.5. INB-100
13.5.3.2.6. GDX012
13.5.3.2.7. AVM0703
13.5.3.2.8. Others
13.5.3.3. India Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trials
13.5.3.3.1. Research
13.5.3.3.2. Preclinical
13.5.3.3.3. Phase-I
13.5.3.3.4. Phase-II/III
13.5.4. New
Zealand
13.5.4.1. New Zealand Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Indication
13.5.4.1.1. Solid Tumor
13.5.4.1.2. Haematological Cancer
13.5.4.1.3. Non-Hodgkin’s lymphoma
13.5.4.1.4. Multiple Myeloma
13.5.4.1.5. Chronic lymphocytic leukemia and Melanoma
13.5.4.1.6. Pancreatic Cancer
13.5.4.1.7. Prostate Cancer
13.5.4.1.8. Colorectal Cancer
13.5.4.1.9. Others
13.5.4.2. New Zealand Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Therapies
13.5.4.2.1. ADI-001
13.5.4.2.2. LAVA-051
13.5.4.2.3. INB-200
13.5.4.2.4. TCB002
13.5.4.2.5. INB-100
13.5.4.2.6. GDX012
13.5.4.2.7. AVM0703
13.5.4.2.8. Others
13.5.4.3. New Zealand Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trials
13.5.4.3.1. Research
13.5.4.3.2. Preclinical
13.5.4.3.3. Phase-I
13.5.4.3.4. Phase-II/III
13.5.5. Australia
13.5.5.1. Australia Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Indication
13.5.5.1.1. Solid Tumor
13.5.5.1.2. Haematological Cancer
13.5.5.1.3. Non-Hodgkin’s lymphoma
13.5.5.1.4. Multiple Myeloma
13.5.5.1.5. Chronic lymphocytic leukemia and Melanoma
13.5.5.1.6. Pancreatic Cancer
13.5.5.1.7. Prostate Cancer
13.5.5.1.8. Colorectal Cancer
13.5.5.1.9. Others
13.5.5.2. Australia Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Therapies
13.5.5.2.1. ADI-001
13.5.5.2.2. LAVA-051
13.5.5.2.3. INB-200
13.5.5.2.4. TCB002
13.5.5.2.5. INB-100
13.5.5.2.6. GDX012
13.5.5.2.7. AVM0703
13.5.5.2.8. Others
13.5.5.3. Australia Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trials
13.5.5.3.1. Research
13.5.5.3.2. Preclinical
13.5.5.3.3. Phase-I
13.5.5.3.4. Phase-II/III
13.5.6. South
Korea
13.5.6.1. South Korea Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Indication
13.5.6.1.1. Solid Tumor
13.5.6.1.2. Haematological Cancer
13.5.6.1.3. Non-Hodgkin’s lymphoma
13.5.6.1.4. Multiple Myeloma
13.5.6.1.5. Chronic lymphocytic leukemia and Melanoma
13.5.6.1.6. Pancreatic Cancer
13.5.6.1.7. Prostate Cancer
13.5.6.1.8. Colorectal Cancer
13.5.6.1.9. Others
13.5.6.2. South Korea Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Therapies
13.5.6.2.1. ADI-001
13.5.6.2.2. LAVA-051
13.5.6.2.3. INB-200
13.5.6.2.4. TCB002
13.5.6.2.5. INB-100
13.5.6.2.6. GDX012
13.5.6.2.7. AVM0703
13.5.6.2.8. Others
13.5.6.3. South Korea Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trials
13.5.6.3.1. Research
13.5.6.3.2. Preclinical
13.5.6.3.3. Phase-I
13.5.6.3.4. Phase-II/III
13.5.7. Southeast
Asia
13.5.7.1. Southeast Asia Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Indication
13.5.7.1.1. Solid Tumor
13.5.7.1.2. Haematological Cancer
13.5.7.1.3. Non-Hodgkin’s lymphoma
13.5.7.1.4. Multiple Myeloma
13.5.7.1.5. Chronic lymphocytic leukemia and Melanoma
13.5.7.1.6. Pancreatic Cancer
13.5.7.1.7. Prostate Cancer
13.5.7.1.8. Colorectal Cancer
13.5.7.1.9. Others
13.5.7.2. Southeast Asia Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Therapies
13.5.7.2.1. ADI-001
13.5.7.2.2. LAVA-051
13.5.7.2.3. INB-200
13.5.7.2.4. TCB002
13.5.7.2.5. INB-100
13.5.7.2.6. GDX012
13.5.7.2.7. AVM0703
13.5.7.2.8. Others
13.5.7.3. Southeast Asia Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trials
13.5.7.3.1. Research
13.5.7.3.2. Preclinical
13.5.7.3.3. Phase-I
13.5.7.3.4. Phase-II/III
13.5.7.4. Southeast Asia Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest of Asia Pacific Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Indication
13.5.8.1.1. Solid Tumor
13.5.8.1.2. Haematological Cancer
13.5.8.1.3. Non-Hodgkin’s lymphoma
13.5.8.1.4. Multiple Myeloma
13.5.8.1.5. Chronic lymphocytic leukemia and Melanoma
13.5.8.1.6. Pancreatic Cancer
13.5.8.1.7. Prostate Cancer
13.5.8.1.8. Colorectal Cancer
13.5.8.1.9. Others
13.5.8.2. Rest of Asia Pacific Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Therapies
13.5.8.2.1. ADI-001
13.5.8.2.2. LAVA-051
13.5.8.2.3. INB-200
13.5.8.2.4. TCB002
13.5.8.2.5. INB-100
13.5.8.2.6. GDX012
13.5.8.2.7. AVM0703
13.5.8.2.8. Others
13.5.8.3. Rest of Asia Pacific Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trials
13.5.8.3.1. Research
13.5.8.3.2. Preclinical
13.5.8.3.3. Phase-I
13.5.8.3.4. Phase-II/III
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By
Clinical Indication
13.6.3. By
Therapies
13.6.4. By
Clinical Trials
14. Middle East and Africa Gamma Delta T Cell Cancer Therapy
Market Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Middle
East and Africa Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn)
14.2. Middle
East and Africa Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Clinical Indication
14.2.1. Solid
Tumor
14.2.2. Haematological
Cancer
14.2.3. Non-Hodgkin’s
lymphoma
14.2.4. Multiple
Myeloma
14.2.5. Chronic
lymphocytic leukemia and Melanoma
14.2.6. Pancreatic
Cancer
14.2.7. Prostate
Cancer
14.2.8. Colorectal
Cancer
14.2.9. Others
14.3. Middle
East and Africa Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapies
14.3.1. ADI-001
14.3.2. LAVA-051
14.3.3. INB-200
14.3.4. TCB002
14.3.5. INB-100
14.3.6. GDX012
14.3.7. AVM0703
14.3.8. Others
14.4. Middle
East and Africa Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Clinical Trials
14.4.1. Research
14.4.2. Preclinical
14.4.3. Phase-I
14.4.4. Phase-II/III
14.5. Middle
East and Africa Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi Arabia Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Indication
14.5.1.1.1. Solid Tumor
14.5.1.1.2. Haematological Cancer
14.5.1.1.3. Non-Hodgkin’s lymphoma
14.5.1.1.4. Multiple Myeloma
14.5.1.1.5. Chronic lymphocytic leukemia and Melanoma
14.5.1.1.6. Pancreatic Cancer
14.5.1.1.7. Prostate Cancer
14.5.1.1.8. Colorectal Cancer
14.5.1.1.9. Others
14.5.1.2. Saudi Arabia Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Therapies
14.5.1.2.1. ADI-001
14.5.1.2.2. LAVA-051
14.5.1.2.3. INB-200
14.5.1.2.4. TCB002
14.5.1.2.5. INB-100
14.5.1.2.6. GDX012
14.5.1.2.7. AVM0703
14.5.1.2.8. Others
14.5.1.3. Saudi Arabia Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trials
14.5.1.3.1. Research
14.5.1.3.2. Preclinical
14.5.1.3.3. Phase-I
14.5.1.3.4. Phase-II/III
14.5.2. UAE
14.5.2.1. UAE Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Indication
14.5.2.1.1. Solid Tumor
14.5.2.1.2. Haematological Cancer
14.5.2.1.3. Non-Hodgkin’s lymphoma
14.5.2.1.4. Multiple Myeloma
14.5.2.1.5. Chronic lymphocytic leukemia and Melanoma
14.5.2.1.6. Pancreatic Cancer
14.5.2.1.7. Prostate Cancer
14.5.2.1.8. Colorectal Cancer
14.5.2.1.9. Others
14.5.2.2. UAE Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn)
and Forecasts, By Therapies
14.5.2.2.1. ADI-001
14.5.2.2.2. LAVA-051
14.5.2.2.3. INB-200
14.5.2.2.4. TCB002
14.5.2.2.5. INB-100
14.5.2.2.6. GDX012
14.5.2.2.7. AVM0703
14.5.2.2.8. Others
14.5.2.3. UAE Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trials
14.5.2.3.1. Research
14.5.2.3.2. Preclinical
14.5.2.3.3. Phase-I
14.5.2.3.4. Phase-II/III
14.5.3. Egypt
14.5.3.1. Egypt Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Indication
14.5.3.1.1. Solid Tumor
14.5.3.1.2. Haematological Cancer
14.5.3.1.3. Non-Hodgkin’s lymphoma
14.5.3.1.4. Multiple Myeloma
14.5.3.1.5. Chronic lymphocytic leukemia and Melanoma
14.5.3.1.6. Pancreatic Cancer
14.5.3.1.7. Prostate Cancer
14.5.3.1.8. Colorectal Cancer
14.5.3.1.9. Others
14.5.3.2. Egypt Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Therapies
14.5.3.2.1. ADI-001
14.5.3.2.2. LAVA-051
14.5.3.2.3. INB-200
14.5.3.2.4. TCB002
14.5.3.2.5. INB-100
14.5.3.2.6. GDX012
14.5.3.2.7. AVM0703
14.5.3.2.8. Others
14.5.3.3. Egypt Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trials
14.5.3.3.1. Research
14.5.3.3.2. Preclinical
14.5.3.3.3. Phase-I
14.5.3.3.4. Phase-II/III
14.5.4. Kuwait
14.5.4.1. Kuwait Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Indication
14.5.4.1.1. Solid Tumor
14.5.4.1.2. Haematological Cancer
14.5.4.1.3. Non-Hodgkin’s lymphoma
14.5.4.1.4. Multiple Myeloma
14.5.4.1.5. Chronic lymphocytic leukemia and Melanoma
14.5.4.1.6. Pancreatic Cancer
14.5.4.1.7. Prostate Cancer
14.5.4.1.8. Colorectal Cancer
14.5.4.1.9. Others
14.5.4.2. Kuwait Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Therapies
14.5.4.2.1. ADI-001
14.5.4.2.2. LAVA-051
14.5.4.2.3. INB-200
14.5.4.2.4. TCB002
14.5.4.2.5. INB-100
14.5.4.2.6. GDX012
14.5.4.2.7. AVM0703
14.5.4.2.8. Others
14.5.4.3. Kuwait Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trials
14.5.4.3.1. Research
14.5.4.3.2. Preclinical
14.5.4.3.3. Phase-I
14.5.4.3.4. Phase-II/III
14.5.5. South
Africa
14.5.5.1. South Africa Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Indication
14.5.5.1.1. Solid Tumor
14.5.5.1.2. Haematological Cancer
14.5.5.1.3. Non-Hodgkin’s lymphoma
14.5.5.1.4. Multiple Myeloma
14.5.5.1.5. Chronic lymphocytic leukemia and Melanoma
14.5.5.1.6. Pancreatic Cancer
14.5.5.1.7. Prostate Cancer
14.5.5.1.8. Colorectal Cancer
14.5.5.1.9. Others
14.5.5.2. South Africa Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Therapies
14.5.5.2.1. ADI-001
14.5.5.2.2. LAVA-051
14.5.5.2.3. INB-200
14.5.5.2.4. TCB002
14.5.5.2.5. INB-100
14.5.5.2.6. GDX012
14.5.5.2.7. AVM0703
14.5.5.2.8. Others
14.5.5.3. South Africa Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trials
14.5.5.3.1. Research
14.5.5.3.2. Preclinical
14.5.5.3.3. Phase-I
14.5.5.3.4. Phase-II/III
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Gamma Delta T Cell Cancer
Therapy Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
14.5.6.1.1. Solid Tumor
14.5.6.1.2. Haematological Cancer
14.5.6.1.3. Non-Hodgkin’s lymphoma
14.5.6.1.4. Multiple Myeloma
14.5.6.1.5. Chronic lymphocytic leukemia and Melanoma
14.5.6.1.6. Pancreatic Cancer
14.5.6.1.7. Prostate Cancer
14.5.6.1.8. Colorectal Cancer
14.5.6.1.9. Others
14.5.6.2. Rest of Middle East & Africa Gamma Delta T Cell Cancer
Therapy Market Revenue (US$ Mn) and Forecasts, By Therapies
14.5.6.2.1. ADI-001
14.5.6.2.2. LAVA-051
14.5.6.2.3. INB-200
14.5.6.2.4. TCB002
14.5.6.2.5. INB-100
14.5.6.2.6. GDX012
14.5.6.2.7. AVM0703
14.5.6.2.8. Others
14.5.6.3. Rest of Middle East & Africa Gamma Delta T Cell Cancer
Therapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trials
14.5.6.3.1. Research
14.5.6.3.2. Preclinical
14.5.6.3.3. Phase-I
14.5.6.3.4. Phase-II/III
14.6. Key Segment
for Channeling Investments
14.6.1. By
Country
14.6.2. By
Clinical Indication
14.6.3. By
Therapies
14.6.4. By
Clinical Trials
15. Latin America Gamma Delta T Cell Cancer Therapy Market
Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Latin
America Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn)
15.2. Latin
America Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Clinical Indication
15.2.1. Solid
Tumor
15.2.2. Haematological
Cancer
15.2.3. Non-Hodgkin’s
lymphoma
15.2.4. Multiple
Myeloma
15.2.5. Chronic
lymphocytic leukemia and Melanoma
15.2.6. Pancreatic
Cancer
15.2.7. Prostate
Cancer
15.2.8. Colorectal
Cancer
15.2.9. Others
15.3. Latin
America Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapies
15.3.1. ADI-001
15.3.2. LAVA-051
15.3.3. INB-200
15.3.4. TCB002
15.3.5. INB-100
15.3.6. GDX012
15.3.7. AVM0703
15.3.8. Others
15.4. Latin
America Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Clinical Trials
15.4.1. Research
15.4.2. Preclinical
15.4.3. Phase-I
15.4.4. Phase-II/III
15.5. Latin
America Gamma Delta T Cell Cancer Therapy Market Revenue (US$ Mn) and
Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Indication
15.5.1.1.1. Solid Tumor
15.5.1.1.2. Haematological Cancer
15.5.1.1.3. Non-Hodgkin’s lymphoma
15.5.1.1.4. Multiple Myeloma
15.5.1.1.5. Chronic lymphocytic leukemia and Melanoma
15.5.1.1.6. Pancreatic Cancer
15.5.1.1.7. Prostate Cancer
15.5.1.1.8. Colorectal Cancer
15.5.1.1.9. Others
15.5.1.2. Brazil Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Therapies
15.5.1.2.1. ADI-001
15.5.1.2.2. LAVA-051
15.5.1.2.3. INB-200
15.5.1.2.4. TCB002
15.5.1.2.5. INB-100
15.5.1.2.6. GDX012
15.5.1.2.7. AVM0703
15.5.1.2.8. Others
15.5.1.3. Brazil Gamma Delta T Cell Cancer Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trials
15.5.1.3.1. Research
15.5.1.3.2. Preclinical
15.5.1.3.3. Phase-I
15.5.1.3.4. Phase-II/III
15.5.2. Argentina
15.5.2.1. Argentina Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Indication
15.5.2.1.1. Solid Tumor
15.5.2.1.2. Haematological Cancer
15.5.2.1.3. Non-Hodgkin’s lymphoma
15.5.2.1.4. Multiple Myeloma
15.5.2.1.5. Chronic lymphocytic leukemia and Melanoma
15.5.2.1.6. Pancreatic Cancer
15.5.2.1.7. Prostate Cancer
15.5.2.1.8. Colorectal Cancer
15.5.2.1.9. Others
15.5.2.2. Argentina Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Therapies
15.5.2.2.1. ADI-001
15.5.2.2.2. LAVA-051
15.5.2.2.3. INB-200
15.5.2.2.4. TCB002
15.5.2.2.5. INB-100
15.5.2.2.6. GDX012
15.5.2.2.7. AVM0703
15.5.2.2.8. Others
15.5.2.3. Argentina Gamma Delta T Cell Cancer Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trials
15.5.2.3.1. Research
15.5.2.3.2. Preclinical
15.5.2.3.3. Phase-I
15.5.2.3.4. Phase-II/III
15.5.3. Rest of
Latin America
15.5.3.1. Rest of Latin America Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Indication
15.5.3.1.1. Solid Tumor
15.5.3.1.2. Haematological Cancer
15.5.3.1.3. Non-Hodgkin’s lymphoma
15.5.3.1.4. Multiple Myeloma
15.5.3.1.5. Chronic lymphocytic leukemia and Melanoma
15.5.3.1.6. Pancreatic Cancer
15.5.3.1.7. Prostate Cancer
15.5.3.1.8. Colorectal Cancer
15.5.3.1.9. Others
15.5.3.2. Rest of Latin America Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Therapies
15.5.3.2.1. ADI-001
15.5.3.2.2. LAVA-051
15.5.3.2.3. INB-200
15.5.3.2.4. TCB002
15.5.3.2.5. INB-100
15.5.3.2.6. GDX012
15.5.3.2.7. AVM0703
15.5.3.2.8. Others
15.5.3.3. Rest of Latin America Gamma Delta T Cell Cancer Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trials
15.5.3.3.1. Research
15.5.3.3.2. Preclinical
15.5.3.3.3. Phase-I
15.5.3.3.4. Phase-II/III
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By
Clinical Indication
15.6.3. By
Therapies
15.6.4. By
Clinical Trials
16. Competitive Benchmarking
16.1. Market
Share Analysis, 2020
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player Profiles
17.1. Acepodia
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Adicet
Bio
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. AVM
Biotechnology
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. Gadeta
Therapeutics
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. GammaDelta
Therapeutics
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT Analysis
17.5.7. Business
Strategies
17.6. IN8bio
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. Kiromic
Biopharma
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. Lava
Therapeutics
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Takeda
Pharmaceuticals
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. TC
Biopharm
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business Strategies
17.11. Other Market
Participants
18. Key Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.